BSX · Boston Scientific Corporation
$62.822026-05-17Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$34
-45.8% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($37 · $51) Analysts Range ($94 · $130) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $11.9B | — | 20.0% | 3.4% | $2.3B | −$1.8B | $478MM | 6.2% | — | 8.6% | $26.7B | $0.70 | — |
| 2022.Q4 | $12.7B | 6.7% | 17.8% | 38.8% | $1.4B | −$2.6B | −$1.2B | 7.3% | — | 5.0% | $28.8B | $0.47 | — |
| 2023.Q4 | $14.2B | 12.3% | 18.9% | 19.8% | $2.2B | −$2.8B | −$669MM | 7.2% | — | 7.2% | $30.9B | $1.06 | — |
| 2024.Q4 | $16.7B | 17.6% | 19.5% | 19.1% | $2.6B | −$5.2B | −$2.6B | 7.8% | — | 7.9% | $35.9B | $1.24 | — |
| 2025.Q4 | $20.1B | 19.9% | 24.5% | 14.6% | $4.2B | −$2.3B | $1.9B | 7.7% | — | 11.2% | $39.0B | $1.93 | 19.1 |
| italics below = DCF projection · 10yr Rev CAGR: 8.7% |
| 2026.Q4 | $22.3B | +10.8% | 24.5% | 15.1% | $4.6B | −$3.7B | $929MM | 7.7% | $862MM | 11.3% | $42.7B | $2.50 | 25.1 |
| 2027.Q4 | $24.6B | +10.5% | 24.9% | 15.7% | $5.2B | −$4.1B | $1.0B | 7.8% | $880MM | 11.5% | $46.8B | $2.79 | 22.5 |
| 2028.Q4 | $27.1B | +10.2% | 26.4% | 16.2% | $6.0B | −$4.6B | $1.4B | 7.9% | $1.1B | 12.2% | $51.5B | $3.24 | 19.4 |
| 2029.Q4 | $29.7B | +9.8% | 26.4% | 16.7% | $6.5B | −$5.3B | $1.2B | 8.0% | $887MM | 12.1% | $56.8B | $3.53 | 17.8 |
| 2030.Q4 | $33.1B | +11.2% | 26.4% | 17.3% | $7.2B | −$7.0B | $240MM | 8.1% | $164MM | 12.0% | $63.8B | $3.90 | 16.1 |
|
| Term. Yr+ | $48.1B | 4.1% | 22.3% | 20.0% | $8.6B | −$4.0B | $4.6B | 8.6% | $47.0B | 8.9% | — | — | — |
Active scenario IV: $34 (-45.8% vs market)